In the past decade, galectin-3 has been widely explored in chronic heart failure setting and has been established as a biomarker independently associated with left ventricular remodeling and adverse prognosis in terms of heart failure-related hospitalizations and increased mortality in this patient cohort [13–15]. The gene discussed is LGALS3; the disease is heart failure.